À¯È¿Ã¼Àû ¹æ¹ý°ú ÀÓ»óºÐ¼®À» ÅëÇÑ ¹æ»ç¼±¿¡ ÀÇÇÑ Á¤»ó ÆóÁ¶Á÷ÀÇ ºÎÀÛ¿ë È®·ü¿¡ °üÇÑ ¿¬±¸
The Study of Normal Tissue Complication Probability(NTCP) for Radiation Pneumonitis by Effective Volume Method

´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1997³â 15±Ç 3È£ p.243 ~ p.250

¾È½Âµµ(Ahn Seung-Do) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÀåÇý¼÷(Chang Hye-Sook) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø ¹æ»ç¼±Á¾¾çÇаú
À̺´¿ë(Yi Byong-Yong) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÃÖÀº°æ(Choi Eun-Kyung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ïÁß¾Óº´¿ø ¹æ»ç¼±Á¾¾çÇаú

Abstract

¸ñ Àû: ¹æ»ç¼±¿¡ ´ëÇÑ Á¤»ó ÆóÁ¶Á÷ÀÇ ºÎÀÛ¿ë¿¡ °üÇÑ È®·üÀº Æó¾ÏÀÇ ¹æ»ç¼± Ä¡·á¿¡ À־ Áß¿äÇÑ ÁöÇ¥°¡ µÊ¿¡µµ ºÒ±¸ÇÏ°í Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. ´õ±¸³ª Ç¥Àû ºÎÀ§¿Í´Â ´Þ¸® Á¤»ó ÆóÁ¶Á÷ÀÇ ¹æ»ç¼±·® ºÐÆ÷´Â ¸Å¿ì ºÒ±ÕÀÏÇϹǷÎ, ´ëÇ¥ ¼±·®°ªÀ» ã¾Æ ³»´Â °ÍÁ¶Â÷ ¾î·Æ´Ù. º» ¿¬±¸¿¡¼­´Â Dose Volume Histogram(DVH)°ú À¯È¿Ã¼Àû¹æ¹ý(Effective Volume Method)À» ÅëÇÏ¿© Á¤»ó ÆóÁ¶Á÷ÀÇ ¼±·®À» Á¤·®È­ÇÏ°í Á¤»ó ÆóÁ¶Á÷ ºÎÀÛ¿ë È®·ü(Normal Tissue Complication Probability, NTCP)À» ±¸ÇÏ¿© ÀÓ»ó°á°ú¿Í ºñ±³ÇϹǷμ­ ÀÌ ¹æ¹ýÀÌ Ä¡·á °á°ú¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÁÖ¿ä ÁöÇ¥·Î¼­ °¡´ÉÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÏ¿© »ìÆì º¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1993³â 8¿ùºÎÅÍ 1994³â 12¿ù±îÁö ºñ¼¼Æ÷¼º Æó¾ÏÀ¸·Î ¹æ»ç¼±°ú º¹ÇÕÇ׾Ͼ๰¿ä¹ýÀ» º´ÇàÇÏ¿© Ä¡·á¹ÞÀº ȯÀÚ Áß¿¡¼­ 36¸íÀ» ¹«ÀÛÀ§ ÃßÃâÇÏ¿©, DVH ºÐ¼®À» ÅëÇÑ Á¤»ó ÆóÁ¶Á÷ÀÇ NTCP¸¦ ±¸ÇÏ¿´´Ù. 36¸íÀÇ È¯ÀÚ´Â Mitomycin C, Vinblastine, CisplatinÀ» »ç¿ëÇÑ 2ȸÀÇ º¹ÇÕÇ׾Ͼ๰¿ä¹ý°ú µ¿½Ã¿¡ ´ÙºÐÇÒ ¹æ»ç¼±Ä¡·á(120cGy/fx, bid)¸¦ 6480cGy±îÁö º´Çà Ä¡·áÇÏ¿´´Ù. °¢ ȯÀÚÀÇ Ä¡·áÀü CT scanÀ» »ç¿ëÇÏ¿© ¿ìÃøÆó, ÁÂÃøÆó ±×¸®°í ÀüüÆó °¢°¢ÀÇ DVH¸¦ ±¸ÇÏ¿´´Ù. Kutcher µîÀÇ Effective Volume Method·Î Nonuniform HistogramÀ» Uniform HistogramÀ¸·Î º¯È¯½ÃÄ×°í, TD50Àº Emami µîÀÇ ÀÚ·á¿¡ ÀÇ°ÅÇÏ¿©, Lyman °ø½ÄÀ» ÀÌ¿ëÇÏ¿© NTCP¸¦ ±¸ÇÏ¿´´Ù. ¹æ»ç¼± Æó·ÅÀÇ Grade´Â SWOGÀÇ Toxicity Criteria¿¡ µû¶ú´Ù.

°á °ú: ´ë»óȯÀÚ 36¸íÁß 6¸íÀÌ Grade I, 2¸íÀÌ Grade IIÀÇ ¹æ»ç¼± Æó·ÅÀÌ ¹ß»ýÇÏ¿´´Ù. ºÎÀÛ¿ëÀÌ ¹ß»ýÇÑ È¯ÀÚ±ºÀÇ NTCP¿Í ¹ß»ýÇÏÁö ¾ÊÀº ȯÀÚ±ºÀÇ NTCP´Â ÀüüÆó¸¦ ´ë»óÀ¸·Î 28.4¿Í 23.4, º´¼Ò ºÎÀ§ÀÇ Æó¸¦ ´ë»óÀ¸·Î 66.0°ú 26.4·Î Åë°èÀûÀ¸·Î À¯ÀÇÇÒ ¸¸ÇÑ Â÷À̸¦ º¸¿´À¸³ª Ä¡·á ÀüÈÄ¿¡ ½ÃÇàÇÑ Æó±â´É °Ë»ç ¼Ò°ß¿¡¼­´Â µÎ ±º »çÀÌ¿¡¼­ Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ ãÁö ¸øÇÏ¿´´Ù.

°á ·Ð: ºÎÀÛ¿ëÀÌ ÀÖ´Â ±º°ú ºÎÀÛ¿ëÀÌ ¾ø´Â ±ºÀÇ NTCP´Â Åë°èÀûÀÎ À¯ÀÇÇÑ Â÷ÀÌ°¡ ÀÖ¾úÀ¸¸çNTCP¿Í ÀÓ»óÀûÀÎ ºÎÀÛ¿ë È®·üÀº Á¤·®ÀûÀ¸·Î ÀÏÄ¡ÇÏ¿´´Ù. ±×·¯³ª NTCP´Â ¼ø¼öÇÏ°Ô ¹æ»ç¼±ÀÇ È¿°ú¸¸À» °í·ÁÇÏ°í ÀÖÀ¸³ª º» ¿¬±¸¿¡¼­´Â Ç׾Ͼ๰¿ä¹ýÀ» º´¿ëÇÏ¿´´Ù´Â°Í°ú ´ÙºÐÇÒ(Hyperfractionation) ¹æ»ç¼± Ä¡·á¿¡ ÀÇÇÑ ¹æ»ç¼± »ý¹°ÇÐÀû º¯È­¿¡ ´ëÇÑ °í·Á°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù. º» ¿¬±¸°á°ú À¯È¿Ã¼Àû ¹æ¹ýÀ» ÀÌ¿ëÇÑ NTCP´Â ÇâÈÄ ÀÔüÁ¶Çü Ä¡·á¿¡¼­ÀÇ ¼±·®Áõ°¡(Dose escalation) °¡´É¼º¿¡ ´ëÇÑ ºÎÀÛ¿ë ¿¹Ãø ÁöÇ¥·Î È°¿ëÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ´Ù.
Purpose: In radiation therapy, NTCP is very important indicator of selecting the optimal treatment plan. In our study, we tried to find out usefullness of NTCP in lung cancer by comparng the incidence of radiation pneumonitis with NTCP.

Methods and Materials: From August 1993 to December 1994, thirty six patients with locally advanced non-small cell lung cancer were treated by concurrent chemoradiation therapy. Total dose of radiation therapy was 6480cGy (120cGy, bid) and chemotherapeutic agents were mitomycin C, vinblastine, cisplatin (2 cycles, 4 weeks interval). We evaluated the development of radiation pneumonitis by CT scan, chest x-ray and clinical symptoms. We used grading system of South Western Oncology Group (SWOG) for radiation pneumonitis. Dose Volume Histograms (DVH) were analyzed for ipsilateral and whole lung. Non uniform DVH was translated to uniform DVH by effective volume method. With these data, we calculated NTCP for ipsilateral and whole lung. Finally we compared the clinical results to NTCP.

Results: Eight of thrity six patients developed radiation pneumonitis. Of these 8 patients, 6 had grade I severity and 2 had grade II. The average NTCP value of the patients who showed radiation pneumonitis was significantly higher than that of the patients without pneumonitis (66% vs. 26.4%). But the results of pulmonary function test was not correlated with NTCP.

Conclusion: NTCP of lung is very good indicator for selecting rival treatment planning in lung cancer. According to the results of NTCP, it may be possible to adjust target volume and optimize target dose. In the near future, we are going to analyze the effect of hyperfractionation and concurrent chemotherapy in addition to NTCP.

Å°¿öµå

Radiation pneumonitis, NTCP
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The average (Normal Tissue Complication Probability, NTCP) value of the patients who showed radiation pneumonitis was significantly higher than that of the patients without pneumonitis (66% vs. 26.4%).
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå